Dental Safety Profile of High-Dose Radioiodine Therapy

Completed

• Conditions: Thyroid Cancer

• Registration Number: NCT00439478
• Lead Sponsor: University Hospital, Basel, Switzerland

Brief Summary

We aim to assess the incidence of oral and dental adverse events after high-dose radioiodine therapy for differentiated thyroid cancer.

Detailed Description

Sialadenitis and xerostomia are the most frequent adverse events of high-dose radioiodine therapy. Saliva has vital functions in maintaining periodontal and oral health. Therefore, xerostomia not only impairs quality of life permanently, but may also increase the risk of caries and tooth extractions. Nevertheless, despite more than 6 decades of radioiodine therapy for thyroid cancer, large studies on long-term oral adverse events are still lacking. In the present study, we investigate the influence of high-dose radioiodine therapy on the long-term oral health.

Study Timeline

• Study Start: 2004-09
• Study Completion: 2006-09
• Study First Submitted: 2007-02-22
• Study First Submitted QC: 2007-02-22
• Study First Posted: 2007-02-23
• Status Verified: 2007-10
• Last Update Submitted: 2007-11-13
• Last Update Posted: 2007-11-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 202

Inclusion Criteria

• histologically confirmed differentiated thyroid cancer
• status after total thyroidectomy
• status after subsequent high-dose radioiodine treatment
• regular follow-up by a board-certified dentist
• a minimum follow-up of 1 year after radioiodine therapy.

Exclusion Criteria

• anaplastic thyroid cancer

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

University Hospital; 🇨🇭 Basel, Switzerland